Stack Pricing · Save Up To 25% + Free Cooler · No Code Needed

Metabolic Research

“Metabolic research” describes a category of peptides and small molecules studied for their effects on the biological systems that govern energy balance, glucose handling, and adipose-tissue biology — not a therapeutic class and not a set of products with established human uses. In this research library the category is represented by six research compounds: GLP-1S, GLP-2T, and GLP-3R, studied in incretin-receptor biology; MOTS-c, a mitochondrial-derived peptide; 5-Amino-1MQ, a small molecule studied in the context of enzyme inhibition; and Tesamorelin, a growth-hormone–releasing hormone analog. What unites them is the family of receptors, enzymes, and signaling pathways their published literature concerns. The overview below explains that underlying science by its proper names, summarizes what the cited research models actually measured, and is explicit throughout about the limits of that evidence — which, for most of the category, is mechanistic and preclinical.

What defines the metabolic-research category

The compounds grouped here do not share a structure, a single mechanism, or a common origin. They are grouped because their research literatures converge on the same set of biological questions: how the body senses nutrient intake, how glucose is regulated, how energy is expended at the cellular level, and how adipose and intestinal tissues participate in those processes. A peptide studied in incretin-receptor signaling, a peptide encoded within mitochondrial DNA, an inhibitor of a methyltransferase enzyme expressed in fat tissue, and a releasing-hormone analog are mechanistically distinct tools — but each is studied as a way to interrogate metabolic physiology.

That framing matters for reading this category honestly. Grouping these compounds is a statement about the research questions they address, not a claim that they are interchangeable or that they share an outcome. The underlying receptor and enzyme science is well documented in the peer-reviewed literature; the compounds themselves are research-supply materials studied against that science, and the two should be kept distinct when reading the evidence.

Incretin biology and GLP-1 receptor signaling

The largest body of biology underlying this category concerns the incretin system. Incretins are gut-derived hormones released in response to nutrient intake; the two principal incretins are glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). A foundational review of incretin biology described how these peptides are synthesized and secreted by enteroendocrine cells and how they act to regulate glucose handling and islet hormone secretion.1 A separate review of incretin pharmacology and physiology characterized GLP-1 and GIP as central regulators of glucose, metabolism, and the secretion of hormones from pancreatic islets.2

GLP-1 itself acts through the GLP-1 receptor, a G-protein–coupled receptor expressed in the pancreas and in numerous other tissues. A widely cited review of GLP-1 mechanisms described the hormone as a regulator of glucose homeostasis that promotes glucose-dependent insulin secretion, influences glucagon, slows gastric emptying, and acts on central pathways involved in appetite.3 These are descriptions of GLP-1 receptor physiology drawn from the scientific literature; they explain why GLP-1 receptor signaling is one of the most intensively studied axes in metabolic research. GLP-1S is a research compound studied in this area; the dedicated GLP-1S research overview covers it individually.

GLP-2 receptor biology and the intestine

Glucagon-like peptide-2 (GLP-2) is produced, like GLP-1, from the proglucagon precursor — in this case by intestinal L cells — but it acts through a different receptor, the GLP-2 receptor, and its documented biology centers on the gut itself. A comprehensive physiology review described GLP-2 as a regulator of intestinal growth and function, with documented effects on mucosal proliferation and the integrity of the intestinal barrier.4 A historical review tracing more than three decades of glucagon-like peptide research likewise described GLP-2’s role in promoting intestinal mucosal growth alongside the better-known glucose biology of GLP-1.5

GLP-2 receptor biology has also been examined for its connection to broader metabolic physiology. A 2024 review discussing the GLP-2 receptor reported research interest in the possibility that GLP-2 receptor activation may improve gut-barrier function and reduce low-grade systemic inflammation — endpoints that connect intestinal biology to whole-body metabolic research.6 GLP-2T is a research compound studied in this GLP-2 receptor area; see the GLP-2T research overview for the compound-specific treatment.

Dual and triple incretin co-agonism as a research concept

One of the most active conceptual threads in incretin research is co-agonism: the idea of a single peptide engineered to activate more than one receptor at once. The rationale is mechanistic — GLP-1, GIP, and the glucagon receptor each contribute differently to metabolic physiology, and research has explored whether engaging several simultaneously produces effects that single-receptor agonists do not.

The dual-incretin concept was established in a study of unimolecular GLP-1/GIP co-agonists, which reported that a balanced co-agonist outperformed single-receptor agonists across rodent, primate, and human experimental models.7 A review of this area, sometimes labeled with the informal term “twincretins,” summarized the biology of dual GIP/GLP-1 receptor activation as a research strategy.8 Research has also extended the concept to triple agonism. In a study of next-generation GLP-1/GIP/glucagon triple agonists, the peptides were reported to increase energy expenditure and reduce body weight in diet-induced-obese mice.9 That is a description of what the study measured in an animal model; it is a research finding in mice, not a statement about any outcome in humans or any product. GLP-3R is a research compound studied in the multi-receptor co-agonism area; the GLP-3R research overview treats it on its own.

MOTS-c: a mitochondrial-derived peptide

MOTS-c belongs to a different and more recently described class. It is a mitochondrial-derived peptide — a short peptide encoded not in the cell nucleus but within mitochondrial DNA. The peptide was characterized in a 2015 study reporting that MOTS-c is a 16-amino-acid peptide encoded within the mitochondrial 12S rRNA region, that it targets skeletal muscle, and that it acts through the folate cycle and AMP-activated protein kinase (AMPK); in that work, MOTS-c was reported to promote metabolic homeostasis and to reduce diet-induced insulin resistance and obesity in mice.10

Subsequent preclinical work extended that picture. A 2019 study in diet-induced-obese mice reported that MOTS-c normalized obesity-elevated metabolic pathways and enhanced insulin sensitivity, characterizing it as a regulator of plasma metabolites.11 A separate study reported that MOTS-c suppresses myostatin and muscle-atrophy signaling through a CK2–PTEN–mTORC2–AKT–FOXO1 pathway, drawing on in-vitro, animal, and human-correlation data.12 A 2023 review of MOTS-c biology summarized its role in glucose metabolism and described its translocation to the cell nucleus under conditions of metabolic stress, where it can influence gene expression.13 Across these studies, MOTS-c is one of the better-replicated preclinical subjects in this category, with consistent cell and rodent findings and some human-correlation data — though, as with the rest of the category, no controlled human efficacy trials. The MOTS-c research overview covers the peptide in detail.

The NNMT-inhibitor research area

A separate metabolic-research thread concerns the enzyme nicotinamide N-methyltransferase (NNMT). NNMT is an enzyme expressed in liver and, notably, in adipose tissue, where it participates in the metabolism of nicotinamide and in NAD+-related biochemistry. Research interest in NNMT comes from genetic and pharmacological work in animal models.

A 2014 study reported that knockdown of NNMT protected mice against diet-induced obesity, with the authors linking the effect to increased energy expenditure and to changes in polyamine flux and NAD+ signaling.14 A later genetic study reported that Nnmt deletion improved insulin sensitivity in male mice fed a high-fat diet.15 Moving from genetics to pharmacology, a 2018 study described selective, membrane-permeable small-molecule inhibitors of NNMT and reported that, in mice, these inhibitors reduced body weight, white-adipose-tissue mass, and adipocyte size in a high-fat-diet model.16

This NNMT-inhibitor literature is the proper scientific context for 5-Amino-1MQ, which is studied as a small-molecule NNMT inhibitor. It is important to be precise here: 5-Amino-1MQ does not itself have a body of direct published primary research under that name. What exists is the broader NNMT-inhibitor literature summarized above — a credible but smaller preclinical base built from genetic knockout work and confirmatory rodent and adipocyte studies. Any discussion of 5-Amino-1MQ is therefore a discussion of the NNMT-inhibition research area as a whole, not of compound-specific studies. The 5-Amino-1MQ research overview places the compound in that context.

Tesamorelin: a GHRH analog

Tesamorelin sits apart from the other compounds in this category in one important way: its published literature is more clinical than preclinical. Tesamorelin is a synthetic analog of growth-hormone–releasing hormone (GHRH). Rather than acting on incretin receptors or mitochondrial pathways, it works upstream of the growth-hormone axis: a review of Tesamorelin described it as a GHRH analog that stimulates the release of endogenous growth hormone and reported that, in the studied context, it was associated with a reduction in visceral adipose tissue.17

The Tesamorelin research overview covers the compound individually.

The honest evidence picture

This is the most important section of any category overview, because the evidence across these compounds is uneven and easy to overstate. The accurate summary has three tiers.

First, the mechanism science is genuine and well documented. Incretin biology — how GLP-1 and GIP are secreted and how their receptors signal — rests on decades of foundational reviews and primary work. GLP-2 receptor biology and its role in intestinal growth are similarly established. NNMT biochemistry and the existence of mitochondrial-derived peptides such as MOTS-c are real, characterized phenomena. None of that is in question, and this article discusses all of it by its proper scientific names.

Second, the research on the specific compounds in this category is predominantly mechanistic and preclinical. The dual- and triple-agonism studies cited here were conducted in cell, rodent, and primate models. The MOTS-c literature is well replicated but consists of in-vitro, mouse, and human-correlation work — not controlled human efficacy trials. The NNMT-inhibitor evidence is a credible but smaller preclinical base, and 5-Amino-1MQ has no direct published studies of its own. Preclinical findings establish biological plausibility and identify mechanisms worth studying; they do not establish that an effect will occur, or be beneficial, in a human or in any specific application.

Third, Tesamorelin is the partial exception: its published literature includes human clinical work, which makes its evidence base more mature than that of the incretin-related or MOTS-c compounds. Even so, the reference cited here is a review of a specific studied context, and a more developed literature is not the same thing as evidence supporting any use of a research-supply material.

So the accurate framing of this category is: a set of mechanistically distinct research compounds whose underlying biology is real and well characterized, but whose own evidence is dominated by animal and in-vitro work — with Tesamorelin’s clinical literature the exception that proves the rule. That is not a temporary gap in this summary’s knowledge; it is the actual state of the published record.

What this does not mean

This article is an educational overview of a research category at the level of documented mechanism and published model systems. It is not medical, veterinary, or scientific advice, and nothing here describes, recommends, or implies use in humans or animals. Where a cited study reported an outcome — a reduction in body weight or in adipose mass in a diet-induced-obese mouse model, for example — that statement is a factual description of what an animal experiment measured, tied to its citation. It is not a claim that any compound described here produces that outcome in people, and it must not be read as one. None of these compounds is described here as a treatment for any human condition. The compounds in this category are sold strictly as research chemicals for in-vitro laboratory research. They are not drugs, supplements, or foods; they are not approved for human or animal use; and they are not intended to diagnose, treat, cure, or prevent any condition.

Frequently asked questions

What does “metabolic research” mean as a category?

It is a grouping of research compounds whose published literatures concern the biology of energy balance, glucose handling, and adipose and intestinal tissue. In this library it covers GLP-1S, GLP-2T, and GLP-3R, together with MOTS-c, 5-Amino-1MQ, and Tesamorelin. The compounds are grouped by the research questions they address, not by a shared structure or a shared outcome — and the category is a research framing, not a therapeutic class.

What is incretin co-agonism?

Co-agonism is the research concept of a single engineered peptide that activates more than one receptor — for example GLP-1 and GIP receptors (dual agonism), or GLP-1, GIP, and the glucagon receptor (triple agonism). The rationale is mechanistic: each receptor contributes differently to metabolic physiology, and research has explored whether engaging several at once produces effects single-receptor agonists do not. The cited studies were conducted in cell, rodent, and primate models.

What makes MOTS-c different from the other compounds?

MOTS-c is a mitochondrial-derived peptide — a short peptide encoded within mitochondrial DNA rather than in the cell nucleus. Research describes it as acting on skeletal muscle through the folate cycle and AMP-activated protein kinase, and it has one of the better-replicated preclinical literatures in this category, spanning in-vitro, mouse, and human-correlation studies. As with the rest of the category, there are no controlled human efficacy trials.

Is there direct research on 5-Amino-1MQ?

There is no body of direct published primary research on 5-Amino-1MQ under that name. It is studied as a small-molecule inhibitor of the enzyme nicotinamide N-methyltransferase (NNMT), and the relevant science is the broader NNMT-inhibitor literature — genetic knockout work and confirmatory rodent and adipocyte studies. Any discussion of 5-Amino-1MQ is a discussion of that NNMT-inhibition research area, not of compound-specific studies.

Why is Tesamorelin’s evidence base described as stronger?

Tesamorelin is a GHRH analog whose published literature includes human clinical work, which makes it more mature than the predominantly preclinical literature of the incretin-related or MOTS-c compounds. A more developed literature is still not evidence supporting any use of a research-supply material; it simply means the published record on Tesamorelin extends further than mechanism and animal models.

What should a laboratory check before sourcing any of these compounds?

Identity and purity, documented on a batch-specific Certificate of Analysis: an HPLC purity result with a chromatogram and a mass-spectrometry result confirming molecular identity, both tied to the lot number on the vial. Our guide on how to read a peptide COA walks through what each section means.

References

  1. Baggio LL, Drucker DJ. Biology of incretins: GLP-1 and GIP. Gastroenterology. 2007. PMID 17498508
  2. Campbell JE, Drucker DJ. Pharmacology, physiology, and mechanisms of incretin hormone action. Cell Metab. 2013. PMID 23684623
  3. Drucker DJ. Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1. Cell Metab. 2018. PMID 29617641
  4. Brubaker PL. Glucagon-like Peptide-2 and the Regulation of Intestinal Growth and Function. Compr Physiol. 2018. PMID 29978894
  5. Drucker DJ. Discovery, characterization, and clinical development of the glucagon-like peptides. J Clin Invest. 2017. PMID 29202475
  6. Pálsson TG, et al. Targeting the GLP-2 receptor in the management of obesity. Peptides. 2024. PMID 38579917
  7. Finan B, et al. Unimolecular dual incretins maximize metabolic benefits in rodents, monkeys, and humans. Sci Transl Med. 2013. PMID 24174327
  8. Skow MA, et al. Diabetes and obesity treatment based on dual incretin receptor activation: ‘twincretins’. Diabetes Obes Metab. 2016. PMID 27160961
  9. Knerr PJ, et al. Next generation GLP-1/GIP/glucagon triple agonists normalize body weight in obese mice. Mol Metab. 2022. PMID 35809773
  10. Lee C, et al. The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell Metab. 2015. PMID 25738459
  11. Kim SJ, et al. The mitochondrial-derived peptide MOTS-c is a regulator of plasma metabolites and enhances insulin sensitivity. Physiol Rep. 2019. PMID 31293078
  12. Kumagai H, et al. MOTS-c reduces myostatin and muscle atrophy signaling. Am J Physiol Endocrinol Metab. 2021. PMID 33554779
  13. Zheng Y, et al. MOTS-c: A promising mitochondrial-derived peptide for therapeutic exploitation. Front Endocrinol. 2023. PMID 36761202
  14. Kraus D, et al. Nicotinamide N-methyltransferase knockdown protects against diet-induced obesity. Nature. 2014. PMID 24717514
  15. Brachs S, et al. Genetic Nicotinamide N-Methyltransferase (Nnmt) Deficiency in Male Mice Improves Insulin Sensitivity in Diet-Induced Obesity. Diabetes. 2019. PMID 30552109
  16. Neelakantan H, et al. Selective and membrane-permeable small molecule inhibitors of nicotinamide N-methyltransferase reverse high fat diet-induced obesity in mice. Biochem Pharmacol. 2018. PMID 29155147
  17. Spooner LM. Tesamorelin: a growth hormone-releasing factor analogue for HIV-associated lipodystrophy. Ann Pharmacother. 2012. PMID 22298602

Continue

Research Use Only. This page is an educational research overview for laboratory and scientific context, and is not medical advice. The compounds described are sold strictly as research chemicals for in-vitro laboratory research. They are not drugs, supplements, or foods, and are not intended for human or animal consumption, diagnosis, treatment, or to prevent any condition.

Cart
Your cart is empty
Shop Peptides →